accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase

HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz, Chronic myelogenous leukemia: a concise update Blood. ,vol. 82, pp. 691- 703 ,(1993) , 10.1182/BLOOD.V82.3.691.691

Russo D, Baccarani M, Sokal Je, Tura S, Staging and prognosis in chronic myelogenous leukemia. Seminars in Hematology. ,vol. 25, pp. 49- 61 ,(1988)

Moshe Talpaz, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers, Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine. ,vol. 354, pp. 2531- 2541 ,(2006) , 10.1056/NEJMOA055229

Francois Guilhot, Jane Apperley, Dong-Wook Kim, Eduardo O. Bullorsky, Michele Baccarani, Gail J. Roboz, Sergio Amadori, Carmino A. de Souza, Jeffrey H. Lipton, Andreas Hochhaus, Dominik Heim, Richard A. Larson, Susan Branford, Martin C. Muller, Prasheen Agarwal, Ashwin Gollerkeri, Moshe Talpaz, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. ,vol. 109, pp. 4143- 4150 ,(2007) , 10.1182/BLOOD-2006-09-046839

Charles L. Sawyers, Chronic Myeloid Leukemia New England Journal of Medicine. ,vol. 340, pp. 1330- 1340 ,(1999) , 10.1056/NEJM199904293401706

Jorge E Cortes, Susan M O'Brien, Francis Giles, Ricardo H Alvarez, Moshe Talpaz, Hagop Kantarjian, Investigational strategies in chronic myelogenous leukemia. Hematology-oncology Clinics of North America. ,vol. 18, pp. 619- 639 ,(2004) , 10.1016/J.HOC.2004.03.004

Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E Bolton, Renaud Capdeville, Brian J Druker, None, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia The New England Journal of Medicine. ,vol. 348, pp. 994- 1004 ,(2003) , 10.1056/NEJMOA022457

Hagop M. Kantarjian, Dennis Dixon, Michael J. Keating, Moshe Talpaz, Ronald S. Walters, Kenneth B. McCredie, Emil J Freireich, Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. ,vol. 61, pp. 1441- 1446 ,(1988) , 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C

Hagop Kantarjian, Francis Giles, Lydia Wunderle, Kapil Bhalla, Susan O'Brien, Barbara Wassmann, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jorge Cortes, Leila Alland, Oliver G. Ottmann, Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL The New England Journal of Medicine. ,vol. 354, pp. 2542- 2551 ,(2006) , 10.1056/NEJMOA055104

E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele, S O'Brien, X Zhou, R Luthra, G Garcia-Manero, F Giles, M B Rios, S Verstovsek, J Cortes, Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia. ,vol. 20, pp. 1767- 1773 ,(2006) , 10.1038/SJ.LEU.2404318